InsuLine Medical Ltd. (TASE: INSL) has signed an investment agreement with Yorkville Advosers LLC for up to $10 million using the REPA mechanism. Insuline develops, produces and markets technologies and products for improve the effectiveness of the insulin injected into diabetes patients.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at email@example.com.
REPA allows ongoing financing in exchange for shares at a pre-agreed price thus not creating pressure on the share price.
Insuline CEO Ron Nagar said, “The investment agreement we have signed allows the company financing flexibility for its business needs ahead of its rapid entry into Germany and due to its non-binding memorandum of understanding with Johnson & Johnson to distribute the InsuPad device.”
Published by www.globes-online.com